The Effect of 12 Weeks of Resistance Training on Some Micro RNAs Associated with Oxidative/Antioxidant System in Liver of Diabetic rats
Mohsen Akbarpourbani1, Fazlollah Fathollahi Shoorabeh2* and Fatemeh Esmail Beigi1
1Faculty of Literature and Humanities, Department of Physical Education and Sports Sciences, Qom University, Iran
2Faculty of Nutrition and Health, Department of Nutrition, Lorestan University of Medical Sciences, Iran
*Corresponding Author: Fazlollah Fathollahi Shoorabeh, Faculty of Nutrition and Health, Department of Nutrition, Lorestan University of Medical Sciences, Iran.
Received:
December 30, 2021; Published: January 24, 2022
Abstract
Introduction: Type 2 diabetes is an epidemic metabolic disease that is estimated to affect about 5 to 8% of adults in the world. One of the main causes of diabetes is fatty liver. The aim of this study was to evaluate the effect of 12 weeks of resistance training on microRNAs related to oxidation and oxidation of the liver of mice with diabetes.
Materials and Methods: In this study, 27 mice with diabetes were divided into control and resistance training groups. The resistance training group performed 5 sessions of resistance training every week for 12 weeks. Real-time PCR method was used to examine the research variables. Results: The results of this study showed that 12 weeks of resistance training significantly reduced the amount of mir-33 (P = 0.001), mir- 34a (P = 0.001) and mir-122 (P = 0.001) were obtained from liver tissue of diabetic mice. Conclusion: Resistance training can prevent liver diseases such as liver cirrhosis by reducing oxidative microRNAs in the liver.
Keywords: Resistance Training; MicroRNAs; Diabetes; Oxidation; Liver
References
- Villanueva A. “Hepatocellular Carcinoma. Reply”. The New England Journal of Medicine (2019): 381, e2.
- ounossi Z., et al. “Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention”. Nature Reviews Gastroenterology and Hepatology 15 (2018): 11-20.
- Zobair M., et al. “Epidemiology of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis: Implications for Liver Transplantation”. Transplantation 103 (2019): 22-27.
- Ounossi ZM., et al. “Global epidemiology of non-alcoholic fatty liver disease-meta-analytic assessment of prevalence, inci- dence, and outcomes”. Hepatology 64 (2016): 73-84.
- Petrick JL., et al. “Have incidence rates of liver cancer peaked in the United States?” Cancer 126 (2020): 3151-3155.
- Estes C., et al. “Modeling the epidemic of non-alcoholic fatty liver disease demonstrates an exponential increase in burden of disease”. Hepatology 67 (2018): 123-133.
- Vogel A., et al. “Hepato-cellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”. Annals of Oncology 30 (2019): 871-873.
- Mitra S., et al. “Epidemiology of non-alcoholic and alcoholic fatty liver diseases”. Translational Gastroenterology and Hepatology (2020): 6-15.
- Evangelista J., et al. “MicroRNAs as Diagnostic Tools in Hepatocellular Carcinoma”. Gastrointestinal Disorders 3 (2021): 237-246.
- Savu L., et al. “Plasma Small Extracellular Vesicles Derived miR-21-5p and miR-92a-3p as Potential Biomarkers for Hepa to cellular Carcinoma Screening”. Frontiers in Genetics 11 (2020): 712.
- Braza-Boils A., et al. “Deregulated hepatic microRNAs underlie the association between non-alcoholic fatty liver disease and coronary artery disease”. Liver International 36 (2016): 1221-1229.
- Jampoka K., et al. “Serum miR-29a andmiR-122 as Potential Biomarkers for Non-Alcoholic Fatty Liver Disease (NAFLD)”. MicroRNA 7 (2018): 215-222.
- Xu X., et al. “The Role of MicroRNAs in Hepatocellular Carcinoma”. Journal of Cancer 9 (2018): 3557-3569.
- Jiang Y., et al. “The Diagnostic Value of MicroRNAs as a Biomarker for Hepatocellular Carcinoma: AMeta-Analysis”. BioMed Research International 2019 (2019): 5179048.
- Castro AP., et al. “Effects of 12 weeks of resistance training on rat gut microbiota composition”. The Journal of Experimental Biology 12 (2021): jeb242543.
- , et al. “MMAB promotes negative feedback control of cholesterol homeostasis”. Nature Communications 12 (2012): 6448.
- Ghareghani P., et al. “Aerobic endurance training improves nonalcoholic fatty liver disease (NAFLD) features via miR-33 dependent autophagy induction in high fat diet fed mice”. Obesity Research and Clinical Practice1 (2017): 80-89.
- , et al. “Effect of aerobic exercise and low carbohydrate diet on pre-diabetic non-alcoholic fatty liver disease in postmenopausal women and middle-aged men - the role of gut microbiota composition: study protocol for the AELC randomized controlled trial”. BMC Public Health 14 (2014): 48.
- Divakaran V and Mann DL. “The emerging role of microRNAs in cardiac remodeling and heart failure”. Circulation Research 103 (2008): 1072-1083.
- Tian X-F., et al. “Activation of the miR-34a/SIRT1/p53 Signaling Pathway Contributes to the Progress of Liver Fibrosis via Inducing Apoptosis in Hepatocytes but Not in HSCs”. PLoS ONE7 (2016): e0158657.
- Chen F and Hu SJ. “Effect of microRNA-34a in cell cycle, differentiation, and apoptosis: a review”. The Journal of Biochemical and Molecular Toxicology2 (2012): 79-86.
- Yan K., et al. “MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo”. PLoS One3 (2012): e33778.
- Qiang J., et al. “miR-34a Regulates the Activity of HIF-1a and P53 Signaling Pathways by Promoting GLUT1in Genetically Improved Farmed Tilapia (GIFT, Oreochromis niloticus) Under Hypoxia Stress”. Frontiers in Physiology 11 (2020): 670.
- Yamada H., et al. “Longitudinal study of circulating miR-122in a rat model of non-alcoholic fatty liver disease”. Clinica Chimica Acta 446 (2015): 267-271.
- Bandiera S., et al. “miR-122 - A key factor and therapeutic target in liver disease”. Journal of Hepatology 62 (2015): 448-457.
- Kalaki-Jouybari F., et al. “High-intensity interval training (HIIT) alleviated NAFLD feature via miR-122 induction in liver of high-fat high-fructose diet induced diabetic rats”. Archives of Physiology and Biochemistry 3 (2020): 242-249.
- Xu J., et al. “Circulating microRNAs, miR-21, miR-122, and miR-223, inpatients with hepatocellular carcinoma or chronic hepatitis”. Molecular Carcinogenesis 50 (2011): 136-142.
Citation
Copyright